TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6152029
Drug: Propiomazine 25
Normalized name: PROPIOMAZINE
DrugBank: Propiomazine (DB00777)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propiomazine 25 mg
Study: 1337553
Drug: Azithromycin, 10
Normalized name: Azithromycin, 100 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 10 mg/Kg/day per os once daily for 3 days or 10 mg/Kg/day on day 1 and 5 mg/Kg/day on days 2-5 (77 patients)
Study: 1337553
Drug: Erythromycin, 50
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 50 mg/Kg/day thrice daily for at least 7 days (74 patients)
Study: 30566442
Drug: Enquiry about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enquiry about clients' medication response
Study: 25230681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low saturated fat intake and high cardiorespiratory fitness
Study: 7596933
Drug: Fluconazole, 400
Normalized name: Fluconazole, 400 mg/200 mL-5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 400 mg/day
Study: 484644
Drug: Anaprox (1,100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaprox (1,100 mg)
Study: 30068215
Drug: Walnut inclusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut inclusion (56 g of walnuts daily for 6 months)
Study: 28441618
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use (alcohol and illicit drugs)
Study: 22540330
Drug: STICA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STICA treatment (manualized short-term treatment of IA/CA)
Study: 343006
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg prazosin
Study: 343006
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prazosin
Study: 19565569
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IGla)
Study: 31301668
Drug: IVT ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IVT ranibizumab (3 injections 0.5 mg)
Study: 31301668
Drug: IVT ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IVT ranibizumab (1 injection 0.5 mg) + LP
Study: 31301668
Drug: Dexamethasone IVT
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone IVT implant (0.7 mg)
Study: 31301668
Drug: Dexamethasone IVT
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone IVT implant (0.7 mg) + LP
Study: 23568174
Drug: Formulation M
Normalized name: Complete Formulation Minis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation M + OPV placebo
Study: 23568174
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations of DTaP-sIPV
Study: 21751165
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate pre-treatment (1.0 g/day for 6 days before and 3 days after radioiodine therapy)
Study: 21751165
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate pre-treatment
Study: 21751165
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with lithium carbonate pre-treatment
Study: 21751165
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lithium treatment)
Study: 16424409
Drug: Salmeterol, 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 42 mug bid via metered-dose inhaler (MDI)
Study: 16424409
Drug: Placebo bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid via metered-dose inhaler (MDI)
Study: 15274385
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m2 plus docetaxel 90 mg/m2 every 3 weeks with prophylactic G‐CSF
Study: 14517197
Drug: Diltiazem HCl
Normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem HCl ER tablets administered in the evening (360 mg single-dose and multiple-dose for 7 days)
Study: 14517197
Drug: Diltiazem HCl
Normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem HCl ER tablets administered in the evening (360 mg once daily for 7 days)
Study: 14517197
Drug: Diltiazem HCl
Normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem HCl ER tablets administered in the evening
Study: 10200003
Drug: LEV 0.1
Normalized name: NuLev 0.125mg Chewable Melt Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 0.1 mg
Study: 10200003
Drug: LEV 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 0.2 mg
Study: 10200003
Drug: LEV 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 0.4 mg
Study: 2156368
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with unprocessed wheat bran (30 g of dietary fiber)
Study: 702130
Drug: Dextroamphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.5 mg/kg)
Study: 1783082
Drug: Placebo elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo elixir
Study: 25805187
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg + low-dose metformin (1000 mg)
Study: 25805187
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (2000 mg)
Study: 25805187
Drug: Linagliptin +
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin + low-dose metformin (1000 mg)
Study: 23856559
Drug: Dronabinol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (maximum dose 28 mg per day, titrated against bodyweight and adverse effects)
Study: 17470688
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with a platinum-based doublet followed by a single agent.
Study: 17470688
Drug: Sequential single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single agents.
Study: 17470688
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy strategy.
Study: 17470688
Drug: Consolidation/maintenance chemotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation/maintenance chemotherapy.
Study: 15104322
Drug: Thermoluminescent dosemeters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermoluminescent dosemeters (TLD) used to assess operators' extremity doses during procedures
Study: 15104322
Drug: Preliminary occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary occupational dose constraint value calculated from cardiologists' annual effective dose
Study: 29885911
Drug: Intra-articular Botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Botulinum toxin injections (30 units)
Study: 19065894
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/d) and Bailing Capsule (2.0 g, twice a day)
Study: 19065894
Drug: Bailing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing Capsule alone
Study: 19065894
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents (control)
Study: 16648320
Drug: 10,000-lux light
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000-lux light treatment and placebo capsule
Study: 16648320
Drug: 100-lux light
Normalized name: mineral oil, light
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-lux light treatment (placebo light) and fluoxetine, 20 mg/day
Study: 10994615
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum pepsinogen I assay and H. pylori IgG serology
Study: 9011452
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment (13-15 mg/kg/day for >3 months)
Study: 9011452
Drug: UDCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA treatment (38+/‐8 months)
Study: 2869470
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg clorazepate dipotassium
Study: 29570501
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at injection speed of 12 mL/h
Study: 29570501
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at injection speed of 60 mL/h
Study: 29570501
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at injection speed of 300 mL/h
Study: 29570501
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at injection speed of 600 mL/h
Study: 29570501
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at injection speed of 1800 mL/h
Study: 26697890
Drug: Mildronate injection
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate injection 250 mg
Study: 26697890
Drug: Mildronate injection
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate injection 500 mg
Study: 26697890
Drug: Mildronate injection
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate injection 750 mg
Study: 26697890
Drug: Multiple-dose mildronate
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose mildronate administration
Study: 22658758
Drug: Normal baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal baseline testosterone (≥10 nmol/l)
Study: 19369866
Drug: Oral glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycerol (GLY)
Study: 19369866
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) and Oral glycerol (GLY)
Study: 17683328
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of hydroxyzine (Atarax) 24 h preoperatively and 3.7 mg/kg hydroxyzine orally on the operation day
Study: 17683328
Drug: 3.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.7 mg/kg hydroxyzine orally only on the operation day
Study: 12196363
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus chemotherapy (TAM-CT group)
Study: 7649959
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at doses of 0.3, 0.6, 0.9 mg/kg
Study: 326385
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone and polychemotherapy (oophorectomy plus modified five-drug 'Cooper' combination)
Study: 326385
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone and polychemotherapy (diethylstilbestrol and cytostatic therapy)
Study: 326385
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus progesterone
Study: 26505681
Drug: XELIRI/FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELIRI/FOLFIRI plus simvastatin (40 mg)
Study: 17827829
Drug: Telmisartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20 mg/day)
Study: 17827829
Drug: Valsartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40 mg/day)
Study: 15214905
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 8 weeks followed by calcipotriol ointment once daily for 4 weeks
Study: 15214905
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 4 weeks followed by calcipotriol ointment once daily on weekdays and the two-compound product once daily at weekends
Study: 15214905
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment twice daily for 12 weeks
Study: 11816704
Drug: Mesoglycan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally for 20 weeks
Study: 9522105
Drug: Cefaclor 25
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 25 mg/kg BID
Study: 9522105
Drug: Amoxicillin-clavulanate 15
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 15 mg/kg TID
Study: 9522105
Drug: Erythromycin 15
Normalized name: erythromycin 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 15 mg/kg TID
Study: 2508608
Drug: Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 10 mg/d
Study: 2508608
Drug: Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 10 mg/d and Tocopherol (vitamin E) 2000 IU/d
Study: 324773
Drug: Phenylbutazone (300‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (300‐400 mg daily)
Study: 27459586
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor inhibitor monotherapy
Study: 27459586
Drug: Castration plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castration plus an androgen receptor inhibitor
Study: 10338176
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lidocaine
Study: 24595146
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg lidocaine
Study: 20117379
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin + omega-3 fatty acids (4 capsules daily)
Study: 17288699
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release (ER) 1000 mg once daily for 5 days
Study: 15801995
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days
Study: 11929392
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg q.d.s.
Study: 2028396
Drug: Postoperative telecobalt
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative telecobalt therapy
Study: 2028396
Drug: Postoperative electron
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative electron therapy
Study: 26652921
Drug: Buccal translation
Normalized name: CONNECTOR,ENFIT TRANSITIONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal translation of maxillary first premolar with 50 g of force
Study: 26652921
Drug: Buccal translation
Normalized name: CONNECTOR,ENFIT TRANSITIONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal translation intervention
Study: 20510026
Drug: Conventional systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional systemic therapy and management of airway (Control)
Study: 16383040
Drug: 1 g/100
Normalized name: Cefotan, 1 g/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/100 cm2 Dermlin topical application
Study: 16383040
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of silver sulfadiazine (SD - Ag) cream
Study: 16383040
Drug: 1 g/100
Normalized name: Cefotan, 1 g/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/100 cm2 Dermlin treatment for diabetic foot ulcers
Study: 16383040
Drug: Cell culture
Normalized name: Rabies - IM Diploid cell culture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell culture with 20 g/L Dermlin
Study: 16383040
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of silver sulfadiazine (SD - Ag) cream in animal test
Study: 12031758
Drug: CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone 10 mg
Study: 10082174
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release capsule (300 mg sodium valproate)
Study: 10082174
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (300 mg sodium valproate)
Study: 10082174
Drug: Enteric-coated tablet
Normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablet (300 mg sodium valproate)
Study: 7788460
Drug: Social milieu
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social milieu treatment
Study: 20217203
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg loading dose administered 24 h before PCI)
Study: 16162709
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (hyperpnea training + endurance training)
Study: 12095312
Drug: 4-Phenylbutyrate (Buphenyl)
Normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Phenylbutyrate (Buphenyl) at doses of 20, 30, or 40 g divided t.i.d. for 1 week
Study: 10726022
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 50 mg
Study: 38175
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs in widespread clinical use for Crohn's disease (specific drugs not mentioned)
Study: 38175
Drug: Prednisone (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (adjusted dose based on illness severity)
Study: 27775407
Drug: Ingroup members'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingroup members' emotional expressions (e.g., fearful, happy, neutral)
Study: 24780615
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 700‐1000 mg iron (according to calculated iron deficit on postoperative day 2)
Study: 24780615
Drug: Ferrous glycine
Normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous glycine sulphate (FS) 100 mg iron daily from day 7 onwards
Study: 10528328
Drug: New dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dopaminergic agonists (carbergolin, pramipexol, ropinirol)
Study: 10528328
Drug: Catechol-O-methyl-transferase (COMT)
Normalized name: 2,3 di-o-methyl-d-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechol-O-methyl-transferase (COMT) inhibitors (entacapone, tolcapone)
Study: 1702663
Drug: 300 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms of selenium in high Se malt cakes daily for one year
Study: 1702663
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of malt cakes daily for one year
Study: 30160651
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor antagonist
Study: 26739331
Drug: Sequential learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential learning using a transparent shoebox for psychomotor skills followed by a box trainer for knot tying.
Study: 25299806
Drug: Modified Network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Network for Improvement of Addiction Treatment (NIATx) change team approach
Study: 22341703
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review by a pharmacist
Study: 19811776
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg d‐cycloserine
Study: 15642799
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg/day)
Study: 15642799
Drug: metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (850 mg, three times a day)
Study: 8039988
Drug: Rectal temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal temperature measurements
Study: 23090093
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Limaprost + NSAIDs)
Study: 22158670
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin C 120 mg, vitamin E 30 mg, beta-carotene 6 mg, selenium 100 μg, zinc 20 mg)
Study: 7824599
Drug: 40% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% sucrose solution
Study: 2969799
Drug: urapidil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (120 mg/day initially, increased to 180 mg/day if necessary)
Study: 2969799
Drug: methyldopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyldopa (100 mg/day initially, increased to 1500 mg/day if necessary)
Study: 21382484
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine with a 4-week interval between doses (MMRV-4W)